Emerging Technology Reports

The Emerging Technology Report provides regular updates about emerging and potentially disruptive technologies that are likely to have a significant impact in healthcare. This “early warning” report monitors new health technologies from 6 months to 2 years within a regulatory submission and tracks those as they go through clinical trial development and the regulatory approval process.

For each emerging technology, our analysts describe the technology and intended use, its prospects relative to the regulatory process and FDA information, competing technologies, relevant clinical guidelines, high-level look at the evidence such as published abstracts in the medical literature and available meeting abstracts, and available clinical trials.

Avastin (Bevacizumab) for Cervical Cancer

Proposed for use in combination with first-line current care chemotherapy for metastatic or recurrent cervical cancer not amenable to curative treatment with surgery and/or radiotherapy.

Orbactiv (Oritavancin)

An intravenous semisynthetic lipoglycopeptide antibiotic administered in a 1-dose regimen to treat acute bacterial skin and skin structure infections in adults.

Phasix Mesh for Hernia Repair

A monofilament, fully resorbable surgical mesh for abdominal hernia repair intended as an alternative to biologic mesh.

Acessa System

A device to perform minimally invasive radiofrequency ablation of uterine fibroids under laparoscopic ultrasound guidance.

Cyramza (Ramucirumab)

An intravenous angiogenesis inhibitor for second-line treatment of advanced gastric or gastroesophageal junction cancer.